Search
Barinthus Biotherapeutics PLC
BRNSAdd to Watchlist
0.740USD
-0.019-2.50%
Close 09-08 16:00（ET）
30.23MMarket Cap
LossP/E TTM
Barinthus Biotherapeutics PLC (BRNS) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Barinthus Biotherapeutics PLC in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
5.000USD+575.58%
BRNS Analyst Recommendation Trends
In the current month, BRNS has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BRNS average Analyst price target in the last month is 5.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
BRNS Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, BRNS EPS is projected to reach -0.260 in FY2026Q3, following reported EPS of -0.259 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.34
-0.28
-0.28
-0.26
-0.27
Actual
-0.27
-0.14
-0.26
--
--
Surprise
+21.28%
+51.64%
+7.50%
--
--
FAQs
What is Barinthus Biotherapeutics PLC's price target?
Analysts forecast that Barinthus Biotherapeutics PLC's price target is USD 5.50, with the highest forecast at USD 7.00 and the lowest forecast at USD 4.00.
How have Barinthus Biotherapeutics PLCBRNS's recent earnings per share performed?
The market expectation was USD -0.26, while Barinthus Biotherapeutics PLCBRNS's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for Barinthus Biotherapeutics PLC?
Based on the ratings of Barinthus Biotherapeutics PLC's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.